AI-driven Deep Genomics gets $180M to turn biology into informational medicines medcitynews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medcitynews.com Daily Mail and Mail on Sunday newspapers.
Peoria, IL, USA 104.9 The Wolf
Courtesy: PeoriaBioMade.org
PEORIA, Ill. Local leaders held an informational meeting Tuesday for Peoria Bio-Made, a push to make the city a global hub in the biotech industry.
Jacob Becraft, co-founder and CEO of Strand Therapeutics, said Peoria is in a unique position to become a central location for the booming industry.
“The community support has truly been humbling since we publicly announced this initiative,” said Becraft.
Becraft went on to say any business should be attracted to Peoria because of the strong sense of “oneness” and community that exists.
Becraft said he wants to see more diverse and STEM opportunities in the Peoria area, which would be created by bringing the biotech business to the area.
Here, in our final post, we provide an analysis of the current landscape and offer conclusions.
Moderna, BioNTech and CureVac –Leading Pioneers
The three largest and best-positioned players in the mRNA space are currently Moderna, BioNTech and CureVac, each having very large patent estates, 11-figure market caps, double-digit candidates in their pipelines, years of development work and accumulated know-how under their belts, and key licenses and other strategic alliances in place for the manufacture, development, and commercialization of mRNA-based products. Moderna and BioNTech (with Pfizer) have each broken through certain regulatory barriers for mRNA with the approvals to commercialize their respective COVID-19 vaccine products, and CureVac is apparently not far behind with a COVID-19 vaccine of its own in Phase 3 clinical trials.
To embed, copy and paste the code into your website or blog:
In Part I of this three-part series, we focused on three mRNA technology market players: BioNTech, Moderna and CureVac. In this second post, we will focus on Translate BIO, Arcturus Therapeutics, and eTheRNA and discuss certain issues relating to lipid nanoparticle (LNP) delivery technology.
More mRNA Market Players
Translate Bio
Translate Bio, Inc. (NASDAQ: TBIO) is headquartered in Lexington, MA, and as of April 2021, has a market capitalization of over $1.3 billion.
According to its website, Translate BIO’s mRNA product pipeline is directed to several indications including cystic fibrosis, primary ciliary dyskinesia, pulmonary arterial hypertension, COVID-19, influenza, viral pathogens, and bacterial pathogens.
Apr 15, 2021
The call came early in the COVID-19 pandemic. Drew Weissman, an infectious diseases professor at the University of Pennsylvania and an expert in messenger RNA, received a query from a Chinese company interested in using the new technology to make a vaccine against the coronavirus.
The technology, which effectively turns the body’s cells into tiny vaccine-making factories, has since become the breakout star of the COVID-19 era, underpinning shots made by Moderna Inc. and the Pfizer Inc./BioNTech SE partnership which have been among the most effective in fighting the disease. Before the coronavirus hit, though, the experimental science had yet to receive regulatory approval for use against any illness let alone against the mysterious infection.